Closed-loop system appears to be safe and superior to usual care in controlling glucose in children with type 1 diabetes

Closed-loop insulin delivery systems improve glucose control in children with type 1 diabetes without causing adverse effects, according to a study presented Saturday at ENDO 2023, the Endocrine Society's annual meeting in Chicago, Ill.

A closed-loop system consists of devices that use a continuous glucose monitor and insulin pump to automatically regulate blood sugar levels for people with diabetes. The system operates "closed-loop" because it continuously monitors and adjusts (starting and stopping) insulin delivery based on the person's blood sugar levels, without the need for manual intervention.

The first closed-loop system was approved for pediatric use in the United States in 2020. Since then, many randomized clinical trials have been performed on closed-loop systems. However, according to study researcher Amanda Godoi from Cardiff University in the United Kingdom, until now no review of studies evaluating the effect of prolonged use of closed-loop systems on glucose levels in children and adolescents with type 1 diabetes has been performed.

Treatment of type 1 diabetes in children is a clinical challenge. We found using closed-loop systems led to improved glucose control, which represents an important treatment opportunity to reduce complications and morbidity in children with type 1 diabetes."

Amanda Godoi, Researcher, Cardiff University

The researchers reviewed nine studies of randomized controlled trials lasting at least 12 weeks comparing closed-loop systems to usual care in a total of 892 children with type 1 diabetes. Usual care is the delivery of insulin through multiple daily insulin injections or sensor augmented pumps, which are commonly used in treating diabetes. These are not automated and thus require the patient to monitor blood sugar levels and adjust the insulin delivery accordingly.

The children and teens using a closed-loop system had a small important 0.35% reduction in HbA1c levels-;a blood test that measures average blood sugar levels over the past three months. They also had an average 9.96% increase in time in an optimal glucose range, without increasing the risk of adverse effects such as hypoglycemia (too-low blood sugar) and diabetic ketoacidosis (a serious complication of diabetes that develops when the body cannot produce enough insulin).

"Our results show that closed-loop technology seems to be safe and superior to usual care in controlling glucose levels," Godoi said.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Combined use of popular diabetes drugs likely to offer additional protection against heart and kidney disease